09.22.25 -- The Future Of Psychedelic-Inspired Therapeutics

Sponsors and CROs are increasingly outsourcing patient recruitment to specialized vendors to address the ongoing challenge of meeting initial recruitment targets on time.

Gene therapies are revolutionizing medicine, with AAV vectors leading the way. As production evolves, stable cell lines may replace transient transfection and unlock scalable solutions.

Delve into the significance of evolving clinical trial models, their potential to remove barriers to participation, and strategies for sponsors to implement hybrid and decentralized designs.

Transitioning from R&D to clinical trials is challenging, but incorporating automation can be a big step toward overcoming technology challenges, streamlining operations, and reducing error rates.

Learn more about addressing substantial challenges in viral vector manufacture and an approach that drives rapid and predictable progression of high-quality viral vector products.